136 related articles for article (PubMed ID: 37963811)
1. Discovery of Orally Bioavailable Phthalazinone Analogues as an ENPP1 Inhibitor for STING-Mediated Cancer Immunotherapy.
Cho Y; Kang M; Ji SH; Jeong HJ; Jung JE; Oh DH; Park S; Park YY; Choi J; Kim S; Kim NJ; Lee DH; Park CS; Han SJ; Lee S; Choi J
J Med Chem; 2023 Nov; 66(22):15141-15170. PubMed ID: 37963811
[TBL] [Abstract][Full Text] [Related]
2. ENPP1 is an innate immune checkpoint of the anticancer cGAMP-STING pathway in breast cancer.
Wang S; Böhnert V; Joseph AJ; Sudaryo V; Skariah G; Swinderman JT; Yu FB; Subramanyam V; Wolf DM; Lyu X; Gilbert LA; Van't Veer LJ; Goodarzi H; Li L
Proc Natl Acad Sci U S A; 2023 Dec; 120(52):e2313693120. PubMed ID: 38117852
[TBL] [Abstract][Full Text] [Related]
3. Development of Novel Ecto-Nucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Inhibitors for Tumor Immunotherapy.
Wang X; Lu X; Yan D; Zhou Y; Tan X
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806118
[TBL] [Abstract][Full Text] [Related]
4. ENPP1, an Old Enzyme with New Functions, and Small Molecule Inhibitors-A STING in the Tale of ENPP1.
Onyedibe KI; Wang M; Sintim HO
Molecules; 2019 Nov; 24(22):. PubMed ID: 31752288
[TBL] [Abstract][Full Text] [Related]
5. Ecto-nucleotide pyrophosphatase/phosphodiesterase 1 inhibitors: Research progress and prospects.
Guan D; Fang L; Feng M; Guo S; Xie L; Chen C; Sun X; Wu Q; Yuan X; Xie Z; Zhou J; Zhang H
Eur J Med Chem; 2024 Mar; 267():116211. PubMed ID: 38359537
[TBL] [Abstract][Full Text] [Related]
6. Discovery of Pyrido[2,3-
Sun Y; Chen M; Han Y; Li W; Ma X; Shi Z; Zhou Y; Xu L; Yu L; Wang Y; Yu J; Diao X; Meng L; Xu S
J Med Chem; 2024 Mar; 67(5):3986-4006. PubMed ID: 38387074
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and biological evaluation studies of novel small molecule ENPP1 inhibitors for cancer immunotherapy.
Gangar M; Goyal S; Raykar D; Khurana P; Martis AM; Goswami A; Ghoshal I; Patel KV; Nagare Y; Raikar S; Mukherjee A; Cyriac R; Paquin JF; Kulkarni A
Bioorg Chem; 2022 Feb; 119():105549. PubMed ID: 34929517
[TBL] [Abstract][Full Text] [Related]
8. AVA-NP-695 Selectively Inhibits ENPP1 to Activate STING Pathway and Abrogate Tumor Metastasis in 4T1 Breast Cancer Syngeneic Mouse Model.
Goswami A; Deb B; Goyal S; Gosavi A; Mali M; Martis AM; Khurana P; Gangar M; Raykar D; Mohanty A; Kulkarni A
Molecules; 2022 Oct; 27(19):. PubMed ID: 36235254
[TBL] [Abstract][Full Text] [Related]
9. Structural insights into cGAMP degradation by Ecto-nucleotide pyrophosphatase phosphodiesterase 1.
Kato K; Nishimasu H; Oikawa D; Hirano S; Hirano H; Kasuya G; Ishitani R; Tokunaga F; Nureki O
Nat Commun; 2018 Oct; 9(1):4424. PubMed ID: 30356045
[TBL] [Abstract][Full Text] [Related]
10. Structure-Aided Development of Small-Molecule Inhibitors of ENPP1, the Extracellular Phosphodiesterase of the Immunotransmitter cGAMP.
Carozza JA; Brown JA; Böhnert V; Fernandez D; AlSaif Y; Mardjuki RE; Smith M; Li L
Cell Chem Biol; 2020 Nov; 27(11):1347-1358.e5. PubMed ID: 32726585
[TBL] [Abstract][Full Text] [Related]
11. Identification of novel pyrrolopyrimidine and pyrrolopyridine derivatives as potent ENPP1 inhibitors.
Jeong HJ; Lee HL; Kim SJ; Jeong JH; Ji SH; Kim HB; Kang M; Chung HW; Park CS; Choo H; Yoon HJ; Kim NJ; Lee DH; Lee SH; Han SJ
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):2434-2451. PubMed ID: 36069240
[TBL] [Abstract][Full Text] [Related]
12. Development of a High-Throughput Assay to Identify Inhibitors of ENPP1.
Kumar M; Lowery RG
SLAS Discov; 2021 Jun; 26(5):740-746. PubMed ID: 33402044
[TBL] [Abstract][Full Text] [Related]
13. Hydrolysis of 2'3'-cGAMP by ENPP1 and design of nonhydrolyzable analogs.
Li L; Yin Q; Kuss P; Maliga Z; Millán JL; Wu H; Mitchison TJ
Nat Chem Biol; 2014 Dec; 10(12):1043-8. PubMed ID: 25344812
[TBL] [Abstract][Full Text] [Related]
14. Targeting ENPP1 for cancer immunotherapy: Killing two birds with one stone.
Huang R; Ning Q; Zhao J; Zhao X; Zeng L; Yi Y; Tang S
Biochem Pharmacol; 2024 Feb; 220():116006. PubMed ID: 38142838
[TBL] [Abstract][Full Text] [Related]
15. ENPP1's regulation of extracellular cGAMP is a ubiquitous mechanism of attenuating STING signaling.
Carozza JA; Cordova AF; Brown JA; AlSaif Y; Böhnert V; Cao X; Mardjuki RE; Skariah G; Fernandez D; Li L
Proc Natl Acad Sci U S A; 2022 May; 119(21):e2119189119. PubMed ID: 35588451
[TBL] [Abstract][Full Text] [Related]
16. ENPP1 Immunobiology as a Therapeutic Target.
Ruiz-Fernández de Córdoba B; Martínez-Monge R; Lecanda F
Clin Cancer Res; 2023 Jun; 29(12):2184-2193. PubMed ID: 36719675
[TBL] [Abstract][Full Text] [Related]
17. Tumor Exosomal ENPP1 Hydrolyzes cGAMP to Inhibit cGAS-STING Signaling.
An Y; Zhu J; Xie Q; Feng J; Gong Y; Fan Q; Cao J; Huang Z; Shi W; Lin Q; Wu L; Yang C; Ji T
Adv Sci (Weinh); 2024 Mar; ():e2308131. PubMed ID: 38498770
[TBL] [Abstract][Full Text] [Related]
18. Development of cGAMP-Luc, a sensitive and precise coupled enzyme assay to measure cGAMP in complex biological samples.
Mardjuki RE; Carozza JA; Li L
J Biol Chem; 2020 Apr; 295(15):4881-4892. PubMed ID: 32127400
[TBL] [Abstract][Full Text] [Related]
19. Identification of the extracellular membrane protein ENPP3 as a major cGAMP hydrolase and innate immune checkpoint.
Mardjuki R; Wang S; Carozza J; Zirak B; Subramanyam V; Abhiraman G; Lyu X; Goodarzi H; Li L
Cell Rep; 2024 May; ():114209. PubMed ID: 38749434
[TBL] [Abstract][Full Text] [Related]
20. Discovery of 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one and 3,4-dihydropyrido[2,3-d]pyrimidin-2(1H)-one derivatives as novel ENPP1 inhibitors.
Jung JE; Jang Y; Jeong HJ; Kim SJ; Park K; Oh DH; Yu A; Park CS; Han SJ
Bioorg Med Chem Lett; 2022 Nov; 75():128947. PubMed ID: 35995398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
